Compare Health Care Select Sector SPDR Fund (XLV) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Health Care Select Sector SPDR Fund vs 22nd Century Group Inc — how do they compare? Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Health Care Select Sector SPDR Fund is far larger — about 69940.6× 22nd Century Group Inc's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Health Care Select Sector SPDR Fund for 100 Days and 22nd Century Group Inc for 32 Days on average.
| XLV | XXII | |
|---|---|---|
Market Cap | $43.48B | $621.67K |
Volume | 11,121,431 | 45,625 |
52-Week High | $175.68 | $483.00 |
52-Week Low | $141.95 | $0.80 |
Typical Hold Time | 100 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLV trades at $170.81, up 1.18% with a bearish technical signal from moving averages. The ETF's low 0.08% expense ratio and healthcare sector diversification provide defensive positioning amid market volatility. Recent options activity shows increased put volume, indicating some investor caution despite healthcare's traditional defensive characteristics during economic uncertainty.
Healthcare sector ETFs like XLV offer defensive exposure with potential upside from demographic trends and innovation. Key risks include political volatility around healthcare policy and concentration in large-cap US stocks. The ETF's cost efficiency and sector positioning make it attractive for long-term investors seeking healthcare exposure.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
